Canada - English - Health Canada

behringwerke ag - albumin - liquid - 50mg - albumin 50mg - blood derivatives

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - bordetella pertussis, inactivated 4 iu/ml; diphtheria toxoid, adsorbed 60 iu/ml; hepatitis b vaccine, rdna 20 µg/ml; tetanus toxoid 120 iu/ml; haemophilus influenzae vaccine, tetanus toxoid conjugate 20 µg/ml - suspension for injection - active: bordetella pertussis, inactivated 4 iu/ml diphtheria toxoid, adsorbed 60 iu/ml hepatitis b vaccine, rdna 20 µg/ml tetanus toxoid 120 iu/ml excipient: aluminium as aluminium phosphate and aluminium hydroxide. phenoxyethanol sodium chloride thiomersal water for injection active: haemophilus influenzae vaccine, tetanus toxoid conjugate 20 µg/ml excipient: lactose monohydrate sodium chloride

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

polygeline 35g

Zimbabwe - English - Medicines Control Authority

glaxosmithkline s.a (pty) ltd - rabies virus (purified chick-embryo cell) - vaccine - 2.5iu

Canada - English - Health Canada

csl behring canada inc - antihemophilic factor (human); von willebrand factor (human) - powder for solution - 300unit; 840unit - antihemophilic factor (human) 300unit; von willebrand factor (human) 840unit - hemostatics

Canada - English - Health Canada

csl behring canada inc - von willebrand factor (human); antihemophilic factor (human) - powder for solution - 1680unit; 600unit - von willebrand factor (human) 1680unit; antihemophilic factor (human) 600unit - hemostatics

Canada - English - Health Canada

csl behring canada inc - antihemophilic factor (human); von willebrand factor (human) - powder for solution - 1200unit; 3360unit - antihemophilic factor (human) 1200unit; von willebrand factor (human) 3360unit - hemostatics

United States - English - NLM (National Library of Medicine)

gsk vaccines gmbh - rabies virus strain flury lep antigen (propiolactone inactivated) (unii: fk894q51ye) (rabies virus strain flury lep antigen (propiolactone inactivated) - unii:fk894q51ye) - rabies virus strain flury lep antigen (propiolactone inactivated) 2.5 [iu] in 1 ml - rabavert is indicated for preexposure vaccination, in both primary series and booster dose, and for postexposure prophylaxis against rabies in all age groups. usually, an immunization series is initiated and completed with one vaccine product. no clinical studies have been conducted that document a change in efficacy or the frequency of adverse reactions when the series is completed with a second vaccine product. however, for booster immunization, rabavert was shown to elicit protective antibody level responses in persons tested who received a primary series with hdcv (4,11). (see also dosage and administration section below) preexposure vaccination consists of three doses of rabavert 1.0 ml, intramuscularly (deltoid region), one each on days 0, 7, and 21 or 28 (1) (see also table 1 for criteria for preexposure vaccination). preexposure vaccination does not eliminate the need for additional therapy after a known rabies exposure (see also dosage and administration section, subsection c). preexposure vaccina

United States - English - NLM (National Library of Medicine)

a-s medication solutions - rabies virus strain flury lep antigen (propiolactone inactivated) (unii: fk894q51ye) (rabies virus strain flury lep antigen (propiolactone inactivated) - unii:fk894q51ye) - rabies virus strain flury lep antigen (propiolactone inactivated) 2.5 [iu] in 1 ml - rabavert is indicated for preexposure vaccination, in both primary series and booster dose, and for postexposure prophylaxis against rabies in all age groups. usually, an immunization series is initiated and completed with one vaccine product. no clinical studies have been conducted that document a change in efficacy or the frequency of adverse reactions when the series is completed with a second vaccine product. however, for booster immunization, rabavert was shown to elicit protective antibody level responses in persons tested who received a primary series with hdcv (4,11). (see also dosage and administration section below) preexposure vaccination consists of three doses of rabavert 1.0 ml, intramuscularly (deltoid region), one each on days 0, 7, and 21 or 28 (1) (see also table 1 for criteria for preexposure vaccination). preexposure vaccination does not eliminate the need for additional therapy after a known rabies exposure (see also dosage and administration section, subsection c). preexposure vaccina

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - histidine-l hydrochloride monohydrate - unknown - histidine-l hydrochloride monohydrate amino acid-histidine active 0.0 - active constituent